other

CagriSema

Novo Nordisk's combination of the long-acting amylin receptor agonist cagrilintide with the GLP-1 agonist semaglutide, in development for diabetes and obesity.

Current clusters

science2 publishers

Novo unveils twelve more GLP-1 and amylin launches through 2030 as 2032 patent cliff looms

The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.

Publishers:genengnews.comstatnews.com

Reality

Evidence64
Adoption34
Hype gap+24
Incentives80
Confidence67